Anebulo appoints Sandra A. Gardiner as Acting CFO via Potrero Hill Advisors agreement

Anebulo Pharmaceuticals, Inc.

Sandra A. Gardiner appointed Acting CFO, principal financial and accounting officer effective March 2, 2023.
Gardiner replaces Rex Merchant; she will provide services through Master Services Agreement with Potrero Hill Advisors.
Gardiner previously served as CFO of Pulse Biosciences (Nasdaq: PLSE) and Cutera, Inc.
Master Services Agreement has five-year term, hourly rate compensation with annual 5% increase option, and 30-day termination notice.
No direct agreement between Company and Gardiner; all terms governed by the consulting arrangement.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Sandra A. Gardiner

Acting Chief Financial Officer

ANEB · Anebulo Pharmaceuticals, Inc.

Effective: 2023-03-02
Filed: March 8, 2023, 6:59 PM ET

On March 2, 2023, the Company appointed Sandra A. Gardiner as the Company’s Acting Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, replacing Rex Merchant in such capacities.

Departed

Rex Merchant

Chief Financial Officer

ANEB · Anebulo Pharmaceuticals, Inc.

Effective: 2023-03-02
Successor: Sandra A. Gardiner
Filed: March 8, 2023, 6:59 PM ET

replacing Rex Merchant in such capacities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sandra A. Gardiner was appointed as Acting Chief Financial Officer at Anebulo Pharmaceuticals, Inc..

Action: appointed
Role: Acting Chief Financial Officer

Exact text from the filing

On March 2, 2023, the Company appointed Sandra A. Gardiner as the Company’s Acting Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, replacing Rex Merchant in such capacities.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.75

Rex Merchant departed as Chief Financial Officer at Anebulo Pharmaceuticals, Inc..

Role: Chief Financial Officer

Exact text from the filing

replacing Rex Merchant in such capacities.

View on SEC.gov

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-006974

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.